Compare · MVST vs TMO
MVST vs TMO
Side-by-side comparison of Microvast Holdings Inc. (MVST) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- MVST operates in Miscellaneous, while TMO operates in Industrials - the two are in different parts of the market.
- TMO is the larger of the two at $222.03B, about 836.6x MVST ($265.4M).
- TMO has been more active in the news (16 items in the past 4 weeks vs 4 for MVST).
- TMO has more recent analyst coverage (25 ratings vs 6 for MVST).
- Company
- Microvast Holdings Inc.
- Thermo Fisher Scientific Inc
- Price
- $0.69-4.72%
- $600.37-2.82%
- Market cap
- $265.4M
- $222.03B
- 1M return
- -16.21%
- -
- 1Y return
- -74.03%
- -
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- 2019
- News (4w)
- 4
- 16
- Recent ratings
- 6
- 25
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest MVST
- Microvast Holdings Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Microvast Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by Microvast Holdings Inc.
- Microvast Reports Second Quarter 2026 Financial Results
- Microvast Holdings Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Microvast Schedules Second Quarter Earnings Call
- SEC Form 25-NSE filed by Microvast Holdings Inc.
- Pres., Gen. Couns. & Corp. Sec Tushe Isida was granted 15,503 shares and sold $7,940 worth of shares (6,403 units at $1.24), increasing direct ownership by 5% to 184,100 units (SEC Form 4) (for tax liability)
- Chief Technology Officer Mattis Wenjuan sold $5,176 worth of shares (4,705 units at $1.10), decreasing direct ownership by 0.50% to 927,973 units (SEC Form 4) (withholding obligation)
- Chief Executive Officer Wu Yang sold $57,428 worth of shares (46,313 units at $1.24), decreasing direct ownership by 0.03% to 134,065,439 units (SEC Form 4) (for withholding tax)
Latest TMO
- Executive Vice President Shafer Michael D covered exercise/tax liability with 790 shares, decreasing direct ownership by 4% to 20,204 units (SEC Form 4)
- SVP and General Counsel Shropshire Thomas B Jr. covered exercise/tax liability with 49 shares, decreasing direct ownership by 0.81% to 6,008 units (SEC Form 4)
- Sr. VP and Chief HR Officer Britt Lisa P. covered exercise/tax liability with 394 shares, decreasing direct ownership by 3% to 14,391 units (SEC Form 4)
- Sr. Vice President & CFO Meyer James covered exercise/tax liability with 270 shares, decreasing direct ownership by 5% to 5,560 units (SEC Form 4)
- Chairman & CEO Casper Marc N covered exercise/tax liability with 1,257 shares, decreasing direct ownership by 1% to 122,669 units (SEC Form 4)
- VP & Chief Accounting Officer Holmes Joseph R. covered exercise/tax liability with 50 shares, decreasing direct ownership by 2% to 2,916 units (SEC Form 4)
- President & COO Pettiti Gianluca covered exercise/tax liability with 1,035 shares, sold $2,539,233 worth of shares (4,133 units at $614.38) as part of a pre-agreed trading plan and exercised 3,733 shares at a strike of $309.63, decreasing direct ownership by 6% to 23,216 units (SEC Form 4)
- Thermo Fisher Scientific to Present at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026
- Chairman & CEO Casper Marc N exercised 275 shares at a strike of $309.63 and sold $172,439 worth of shares (275 units at $627.05) as part of a pre-agreed trading plan (SEC Form 4)
- Sr. Vice President & CFO Meyer James covered exercise/tax liability with 31 shares, decreasing direct ownership by 0.53% to 5,830 units (SEC Form 4)